Will the Phase 2 trial "Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC" reach primary completion on or before Mar 1, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06371586 (Cancer Institute and Hospital, Chinese Academy of Medical Sciences) shows an actual primary completion date on or before Mar 1, 2027. Registered date at generation: Mar 1, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Mar 1, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.